Alzheimer's Disease/Cognition News

Individuals diagnosed with glaucoma may benefit from increased monitoring for dementia symptoms, particularly if they were diagnosed at age 80 years or older, according to a study in Ophthalmology.

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.

An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.

Prothena Corp. recently announced it would receive $80 million from Bristol Myers Squibb for an exclusive global license to an investigational therapeutic developed to address protein dysregulation.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

Women diagnosed with preeclampsia were 2.6 times more likely to develop early-onset dementia during 9 years of follow-up compared with women who did not have a hypertensive disorder of pregnancy, according to registry data.

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

AC Immune SA ad Takeda have announced an exclusive, worldwide option and license agreement for the former’s active immunotherapies that target toxic forms of the biomarker amyloid beta to treat Alzheimer’s disease.